Prudentia Sciences provides an AI-powered platform that optimizes drug pipelines and enhances dealmaking in the life sciences sector by offering rapid asset diligence and valuation capabilities.

Axonis Therapeutics is a biotechnology company developing novel neuromedicines targeting neurological disorders like epilepsy and pain.

Zafrens is a drug discovery company that specializes in a high-throughput, high-resolution Z-Screen™ platform for analyzing CRISPR, CAR-T, mRNA libraries, and molecular heterogeneity, aiming to develop RNA-modulatory small molecules and TCR libraries for cancer treatment and seeking partnerships to expand its technology's applications.